Publicação científica trimestral do CREMERJ

42 Tratamento do diabetes tipo 2: tendências atuais Alessandra Saldanha de Mattos Matheus Med. Ciên. e Arte , Rio de Janeiro, v.1, n.1, p.25-44, jan-mar 2022 20. Rosenstock J, Kahn SE, Johansen OE et al. for the CAROLINA Investigators. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA 2019 Sep 19. doi: 10.1001/jama.2019.13772. 21. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: double- blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34:535–42. 22. Gangji AS; Cukierman T; Gerstein HC et al. A systematic review and meta analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30:389-394. 23. Gross JL, Kramer CK, Leitão CB et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011; 154(10):672-9. 24. Khardori R, Griffing GT. Type 2 Diabetes Mellitus Treatment &Management: Approach Considerations, Pharmacologic Therapy, Management of Glycemia. Acessado em 20/08/2021 https://emedicine.medscape . com/article/117853-treatment#d9 14/ 25. DiNicolantonio JJ, Bhutani J, O’Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular out-comes. Open Heart. 2 2015; http://dx.doi.org/10.1136/ openhrt-2015-0003.27. 26. Chiasson JL, Josse RG, Gomis R et al., Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucosetolerance: The STOP-NIDDM trial, JAMA 290 2003; 486-494. 27. Nissen SE, Nicholls SJ, Wolski K, et al; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes the PERISCOPE randomized controlled trial. JAMA 2008; 299(13):1561-1573. 28. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493):1279-89. 29. Charbonnel B, Schernthaner G, Brunetti P et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48: 1093-1104. 30. Phung OJ, Sood NA, Sill BE, Coleman CI. Oral anti-diabetic drugs for the prevention of Type 2 diabetes. Diabet Med. 2011; 28(8):948-64. 31. Lewis JD, Ferrara A, Peng T et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011; 34(4):916-22. 32. Levin PA, Nguyen H, Wittbrodt ET et al. Glucagon-like peptide-1 receptor agonists: A systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes 2017; 10: 123-139. 33. Wilcox T,De Block C, Schwartzbard AZ et al. Diabetic Agents, From Metformin To SGLT2 Inhibitors and GLP1 Receptor Agonists. J Amer College of Cardiology 2020; . 7 5(1 6). 34. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375 (4):311-22. 35. Mann JFE, Ørsted DD, Buse JB. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839-848. 36. Tamborlane WV, Barrientos-Perez M, Fainberg U, et al. Liraglutide in Children and Adolescents with Type 2 Diabetes . N Engl J Med. 2019 Apr 28. 37. Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014; 37(8):2168-76.